Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Clearmind Medicine Inc.

< Previous 1 2 3 4 Next >
Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND PLRZ
Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND SPRC
Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Announces Shareholders Meeting Results
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND SPRC
Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND CSE:CMND
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.